AT423112T - Dipyridyl-dihydropyrazolone and their use of 4- (pyridin-3-yl) -2- (pyridin-2-yl) -1,2-dihydro-3h-pyrazol-3-on derivatives as specific hif prolyl-4 inhibitors hydroxylases for the treatment of cardiovascular and hematological diseases - Google Patents

Dipyridyl-dihydropyrazolone and their use of 4- (pyridin-3-yl) -2- (pyridin-2-yl) -1,2-dihydro-3h-pyrazol-3-on derivatives as specific hif prolyl-4 inhibitors hydroxylases for the treatment of cardiovascular and hematological diseases

Info

Publication number
AT423112T
AT423112T AT06724361T AT06724361T AT423112T AT 423112 T AT423112 T AT 423112T AT 06724361 T AT06724361 T AT 06724361T AT 06724361 T AT06724361 T AT 06724361T AT 423112 T AT423112 T AT 423112T
Authority
AT
Austria
Prior art keywords
pyridin
yl
dihydropyrazolone
hydroxylases
dipyridyl
Prior art date
Application number
AT06724361T
Other languages
German (de)
Inventor
Ingo Flamme
Jens-Kerim Ergueden
Felix Oehme
Kai Thede
Gunter Karig
Alexander Kuhl
Hanno Wild
Joachim Schuhmacher
Peter Kolkhof
Lars Baerfacker
Joachim Huetter
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE102005019712A priority Critical patent/DE102005019712A1/en
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of AT423112T publication Critical patent/AT423112T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
AT06724361T 2005-04-28 2006-04-15 Dipyridyl-dihydropyrazolone and their use of 4- (pyridin-3-yl) -2- (pyridin-2-yl) -1,2-dihydro-3h-pyrazol-3-on derivatives as specific hif prolyl-4 inhibitors hydroxylases for the treatment of cardiovascular and hematological diseases AT423112T (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE102005019712A DE102005019712A1 (en) 2005-04-28 2005-04-28 Dipyridyl-dihydropyrazolone and its use

Publications (1)

Publication Number Publication Date
AT423112T true AT423112T (en) 2009-03-15

Family

ID=36889059

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06724361T AT423112T (en) 2005-04-28 2006-04-15 Dipyridyl-dihydropyrazolone and their use of 4- (pyridin-3-yl) -2- (pyridin-2-yl) -1,2-dihydro-3h-pyrazol-3-on derivatives as specific hif prolyl-4 inhibitors hydroxylases for the treatment of cardiovascular and hematological diseases

Country Status (18)

Country Link
US (2) US8252817B2 (en)
EP (1) EP1877396B1 (en)
JP (1) JP5112294B2 (en)
KR (1) KR101332939B1 (en)
CN (1) CN101213189B (en)
AT (1) AT423112T (en)
AU (1) AU2006239580A1 (en)
BR (1) BRPI0611154A2 (en)
CA (1) CA2608099C (en)
DE (2) DE102005019712A1 (en)
DK (1) DK1877396T3 (en)
ES (1) ES2320930T3 (en)
HK (1) HK1122803A1 (en)
IL (1) IL186907D0 (en)
MX (1) MX2007013342A (en)
PL (1) PL1877396T3 (en)
PT (1) PT1877396E (en)
WO (1) WO2006114213A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005019712A1 (en) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone and its use
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
WO2008002576A2 (en) 2006-06-26 2008-01-03 The Procter & Gamble Company Prolyl hydroxylase inhibitors and methods of use
DE102006050513A1 (en) 2006-10-26 2008-04-30 Bayer Healthcare Ag New substituted dihydropyrazolone derivatives are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat/prevent e.g. cardiovascular diseases, heart-circulation diseases, heart failure and anemia
DE102006050515A1 (en) 2006-10-26 2008-04-30 Bayer Healthcare Ag New substituted dipyridiyl-dihydropyrazolone derivatives are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat/prevent e.g. cardiovascular diseases, heart-circulation diseases, heart failure and anemia
DE102006050516A1 (en) 2006-10-26 2008-04-30 Bayer Healthcare Ag New pyrazol-3-one compounds are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful e.g. to treat and/or prophylaxis heart-circulation diseases, heart failure, anemia, chronic kidney diseases and renal failure
ES2546815T3 (en) 2006-12-15 2015-09-28 Bristol-Myers Squibb Company Analogs of arylpropylamide, arylacrylamide, arylpropinamide or arylmethylurea as inhibitors of factor XIa
CA2685942A1 (en) * 2007-05-16 2008-11-27 Merck & Co., Inc. Spiroindalones
WO2008157177A1 (en) * 2007-06-13 2008-12-24 The Uab Research Foundation Methods for modulating osteoblast cell differentiation and bone generation through inhibition of a prolyl hydroxylase
US20110123481A1 (en) * 2007-08-16 2011-05-26 Remedor Biomed Ltd. Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications
DE102007044032A1 (en) 2007-09-14 2009-03-19 Bayer Healthcare Ag New substituted heteroaryl compounds are hypoxia-inducible factor prolyl-4-hydroxylase inhibitors useful to treat and/or prevent e.g. circulatory heart diseases, heart failure, anemia, chronic kidney diseases and renal failure
DE102007048447A1 (en) 2007-10-10 2009-04-16 Bayer Healthcare Ag New substituted dihydropyrazole-3-thione compounds are hypoxia inducible factor-prolyl-4-hydroxylase inhibitor, useful for preparing medicament to treat and/or prevent e.g. cardiovascular diseases, wound healing and anemia
DE102008020113A1 (en) 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituted dihydropyrazolones and their use
JP6022769B2 (en) * 2008-04-28 2016-11-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap Benzimidazoles as prolyl hydroxylase inhibitors
CA2719234A1 (en) * 2008-05-08 2009-11-12 Joan M. Fletcher Spiroazaindoles
EP2135865A1 (en) 2008-06-17 2009-12-23 Bayer CropScience AG Substituted 1-(diazinyl)pyrazol-4-yl acetic acids, method for their production and their use as herbicides and plant growth regulators
EP2311822A4 (en) 2008-08-01 2011-08-31 Nippon Chemiphar Co Gpr119 agonist
US8598209B2 (en) * 2008-10-31 2013-12-03 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
EP2194052A1 (en) 2008-12-06 2010-06-09 Bayer CropScience AG Substituted 1.(1-thiazolyl)- and 1-(isothiazolyl)pyrazol-4-yl acetic acids, method for their production and their use as herbicides and plant growth regulators
EP2382215B1 (en) 2008-12-29 2014-07-16 Sanofi Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof
MX2011007054A (en) * 2008-12-29 2011-11-29 Sanofi Sa Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof as hif activators.
FR2940651B1 (en) * 2008-12-29 2013-05-03 Sanofi Aventis 2-pyridin-2-yl-pyrazol-3 (2h) -one derivatives, their preparation and their therapeutic use as hif activators
FR2949466A1 (en) * 2009-08-28 2011-03-04 Sanofi Aventis New 2-pyridin-2-yl-pyrazol-3(2H)-one compounds are hypoxia inducible factor activators useful to treat e.g. lower limb ischemia, angina pectoris, myocardial infarction, atherosclerosis, pulmonary hypertension, glaucoma and kidney diseases
US20120245344A1 (en) 2009-08-31 2012-09-27 Nippon Chemiphar Co., Ltd. Gpr119 agonist
AU2010307006B2 (en) 2009-10-13 2016-08-11 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses
MX2012005275A (en) 2009-11-06 2012-06-19 Aerpio Therapeutics Inc Compositions and methods for treating colitis.
WO2011073098A1 (en) 2009-12-15 2011-06-23 Bayer Cropscience Ag 1-(heteroaryl)-pyrazol-4-yl-acetic acids, method for the production thereof, and the use thereof as herbicides and plant growth regulators
CN103052628B (en) 2010-07-20 2016-05-18 韦斯塔隆公司 Triazines and pyrimidines insecticides
WO2012052412A1 (en) * 2010-10-22 2012-04-26 Bayer Cropscience Ag Novel heterocyclic compounds as pesticides
DE102010044131A1 (en) 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituted sodium 1H-pyrazole-5-olate
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
JP2014522410A (en) 2011-06-06 2014-09-04 アケビア セラピューティクス インコーポレイテッドAkebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia-inducible factor-2α as a method for cancer treatment
NO2686520T3 (en) 2011-06-06 2018-03-17
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
JP6126078B2 (en) * 2012-03-30 2017-05-10 第一三共株式会社 4-alkanoylamino-3-pyrazolone derivatives
CN104507910B (en) 2012-07-30 2016-06-15 大正制药株式会社 Partially saturated nitrogen-containing heterocyclic compounds
US8734250B2 (en) 2012-10-05 2014-05-27 Wargaming.Net Llp Control of vehicles in three dimensional space
TR201802632T4 (en) 2013-03-29 2018-03-21 Takeda Pharmaceuticals Co 6- (5-hydroxy-1H-pyrazol-1-yl) nicotinamide derivatives and their use as inhibitors of PHD.
CN103396365A (en) * 2013-08-06 2013-11-20 新乡学院 Synthesis method of pyrazolone
AR099354A1 (en) 2013-11-15 2016-07-20 Akebia Therapeutics Inc solid forms of {[5- (3-chlorophenyl) -3-hydroxypyridine-2-carbonyl] amino} acetic acid, compositions, and their uses
CN103755587B (en) * 2014-01-06 2015-06-10 华东师范大学 Derivatives of 4-polyfluoroalkyl-2,4-disubstituted pyrrole and preparation method thereof
EP2957283A1 (en) 2014-06-19 2015-12-23 Symrise AG Medicament for acceleration of wound healing
US10065928B2 (en) 2014-09-02 2018-09-04 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof
CA2974691A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
CN105218437A (en) * 2015-10-31 2016-01-06 高大元 Synthesis method of 3-cloro-5-bromo-2-picolinic acid

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL103509B1 (en) * 1976-09-20 1979-06-30 herbicide
US4075003A (en) * 1975-12-11 1978-02-21 Eli Lilly And Company Novel herbicidal method utilizing 1,4-diphenyl-3-pyrazolin-5-ones
GR63123B (en) 1975-12-11 1979-09-11 Lilly Co Eli Preparation process of novel 1,4-diphenyl-3-pyrazolin-5-ones
US4663327A (en) 1984-05-23 1987-05-05 Bayer Aktiengesellschaft 1-heteroaryl-4-aryl-pyrazolin-5-ones
DE3443308A1 (en) * 1984-11-28 1986-05-28 Bayer Ag 1-heteroaryl-4-aryl-pyrazolin-5-one for use as medicaments
DE3527157A1 (en) * 1985-07-30 1987-02-12 Bayer Ag 1-heteroaryl-4-aryl-pyrazole derivatives
FR2725988B1 (en) 1994-10-24 1997-01-24 Roussel Uclaf New derivatives of pyrazoles and pyrazolones acids, their method of preparing the new intermediaries obtained, their application as medicines and pharmaceutical compositions containing them
DE19909237A1 (en) 1999-03-03 2000-09-07 Merck Patent Gmbh Pyrazol-3-one derivatives
WO2002074981A2 (en) * 2001-03-21 2002-09-26 Isis Innovation Ltd. Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
US6878729B2 (en) * 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
CA2446864C (en) * 2001-05-16 2011-02-15 Vertex Pharmaceuticals Incorporated Inhibitors of src and other protein kinases
EP1487472B1 (en) * 2001-12-06 2019-06-26 Fibrogen, Inc. Treatment of ischemic or hypoxic conditions using heterocyclic carboxamides
CA2469813C (en) 2001-12-18 2009-02-24 Merck & Co., Inc. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
AU2003213673A1 (en) 2002-03-01 2003-09-16 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
GB0206711D0 (en) * 2002-03-21 2002-05-01 Isis Innovation HIF Inhibitor
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
EP1613311A4 (en) 2003-03-27 2010-04-14 Univ Emory Hif-1 inhibitors
CA2520870A1 (en) 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
EP1626718A4 (en) * 2003-05-01 2010-05-05 Panacea Pharmaceuticals Inc Methods of treating ischemic related conditions
JP4499721B2 (en) * 2003-06-30 2010-07-07 ビズバイオテク シーオー.,エルティーディー. Compounds, compositions and methods
WO2006088491A2 (en) * 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
AT504818A1 (en) 2004-07-30 2008-08-15 Windtec Consulting Gmbh Transmission trail of a wind power plant
CN101171235B (en) 2005-03-16 2011-03-02 安万特药物公司 Dipyrazoles as central nervous system agents
DE102005019712A1 (en) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone and its use
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
DE102006050515A1 (en) * 2006-10-26 2008-04-30 Bayer Healthcare Ag New substituted dipyridiyl-dihydropyrazolone derivatives are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat/prevent e.g. cardiovascular diseases, heart-circulation diseases, heart failure and anemia
DE102006050513A1 (en) 2006-10-26 2008-04-30 Bayer Healthcare Ag New substituted dihydropyrazolone derivatives are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat/prevent e.g. cardiovascular diseases, heart-circulation diseases, heart failure and anemia
DE102008020113A1 (en) 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituted dihydropyrazolones and their use

Also Published As

Publication number Publication date
PL1877396T3 (en) 2009-10-30
HK1122803A1 (en) 2012-05-04
US20100035906A1 (en) 2010-02-11
US20120322772A1 (en) 2012-12-20
KR20080007482A (en) 2008-01-21
CA2608099C (en) 2013-10-01
CA2608099A1 (en) 2006-11-02
DE502006002886D1 (en) 2009-04-02
JP5112294B2 (en) 2013-01-09
EP1877396B1 (en) 2009-02-18
PT1877396E (en) 2009-04-13
ES2320930T3 (en) 2009-05-29
WO2006114213A1 (en) 2006-11-02
US8252817B2 (en) 2012-08-28
US9085572B2 (en) 2015-07-21
CN101213189B (en) 2011-06-22
AU2006239580A1 (en) 2006-11-02
DE102005019712A1 (en) 2006-11-09
CN101213189A (en) 2008-07-02
EP1877396A1 (en) 2008-01-16
MX2007013342A (en) 2008-01-18
KR101332939B1 (en) 2013-11-26
JP2008539180A (en) 2008-11-13
DK1877396T3 (en) 2009-04-27
IL186907D0 (en) 2008-02-09
BRPI0611154A2 (en) 2010-08-17

Similar Documents

Publication Publication Date Title
DK1874282T3 (en) Methods and Preparations for the Treatment of CNS Disorders
DK1581532T3 (en) Pyrazolo-3,4-B pyridine compounds and their use as phosphodiesterase inhibitors
DK1911756T3 (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DK1962830T3 (en) Azaindole inhibitors of aurorakinases.
DK1969359T3 (en) Biosensors and methods for their preparation and use
DK1853271T3 (en) Method and Preparation for the Treatment of Peripheral Vascular Diseases
DK1749011T3 (en) Bicyclic heterocycles as HIV integrase inhibitors
DK1711181T3 (en) Quinoline derivatives and their use as mycobacterial inhibitors
DK1776349T3 (en) 2-Amino-Puinazoline Derivatives Usable as Inhibitors of Beta-Secretase (BACE)
DK1928438T3 (en) Use of ibudilast for the treatment of drug dependence
NZ739339A (en) Apoptosis signal-regulating kinase inhibitor
PT2349260E (en) Janus kinase inhibitors for treatment of dry eye and other eye related diseases
DE602005022116D1 (en) 5-heteroarylthiazole and their use as pi3k inhibitors
ZA200700223B (en) Quinazolin-4-yl-piperidine and cinnolin-4-yl-peperidine derivatives as PDE10 inhibitors for the treatment of CNS disorders
DE602005020645D1 (en) Compositions and methods for tumor diagnosis and treatment
AT519488T (en) Aminopyracin analogue for the treatment of gluckoms and other diseases caused by rho-kinase
IL190935D0 (en) 4-(3-aminopyrazole)pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
AT557021T (en) Derivatives of 4-piperazin-1-yl-4-benzoethiophone suitable for the treatment of cns disorders
HK1129890A1 (en) C-met protein kinase inhibitors for the treatment of proliferative disorders
EA201001769A1 (en) Derivatives of quinolines and quinoxalins as proteinthyrosinkinase inhibitors
DK1928886T3 (en) Pyridine derivatives and their use in the treatment of psychotic disorders
BRPI0716981A2 (en) Kinase inhibitors useful for treatment of proliferative diseases
DK1841757T3 (en) Heteroaromatic quinoline compounds and their use as PDE10 inhibitors
HK1158650A1 (en) Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2- (trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3- carboxamide n-(4-(7-[221]-7-)-2-())-4--5-()-1 4--3-
AT523492T (en) Chinoline and chinoxaline derivatives as inhibitors of enzymatic kinase activity

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner